Mice injected with CRIg-Ig developed less-severe liver injury (Fig. 5b), steatosis (Fig. 5c, d), hepatic inflammation (Fig. 5e–g) and systemic inflammation (Fig. 5h) than mice given the control-Ig but had no change in hepatic levels of CRIg or intestinal absorption or hepatic metabolism of ethanol (Fig. 5i–k). Here, VSIG4 is linked to steatosis.